86例口服伏立康唑患者的不良反应观察与分析  

Observation and analysis of adverse reactions of oral voriconazole in 86 patients

作　　者：刘蕾[1] 钱效森[2] 赵学增[1] 孙瑞芳[1] 

机构地区：[1]民航总医院药剂科,北京100123 [2]民航总医院呼吸科,北京100123

出　　处：《中国医院药学杂志》2015年第16期1502-1505,共4页Chinese Journal of Hospital Pharmacy

摘　　要：目的:重点监测伏立康唑药品不良反应(ADR),进一步评价伏立康唑的安全性,为合理用药提供参考。方法:2012年1月—2013年12月,临床药师在呼吸科病房对86例应用伏立康唑的患者给予药学监护,重点监测ADR。对应用伏立康唑前后进行相关的实验室检查,参考我国药品ADR监测中心指定的药物ADR判断标准,对患者的用药情况,ADR发生时间、临床表现、处理方法及转归情况进行描述性分析。结果:86例患者中27例发生伏立康唑相关ADR,ADR发生率为31.40%,其中男性发生率高于女性;80岁以上老年患者伏立康唑ADR发生率最高;由于相互作用导致严重ADR2例;ADR可发生在用药后的各个时间段,且累及多个系统-器官。结论:伏立康唑ADR较多,且易发生药物相互作用。通过重点监测,使医务人员对伏立康唑ADR的发生规律、临床特征及危险因素有了更加深入的认识,增加了伏立康唑ADR的暴露率,临床药师以此为切入点提供药学专业知识,促进临床合理用药。OBJECTIVE To mainly monitor voriconazole induced adverse reactions and further evaluate voriconazole to provide references for clinical rational drug use. METHODS From January 2012 to December 2013, clinical pharmacists took pharmaceutical care for 86 patients who received voriconazole, and focused on monitoring ADR in respiratory department. Related laboratory tests were conducted before and after administration of voriconazole, situation of drug use, occurrence time, clinical manifestations, treatment and clinical outcome of ADR were described and evaluated according to standard established by national ADR monitor center. RESULTS Twenty seven from 86 patients had ADR related to voriconazole, and incidence of ADR was 31.4%. Male patients were more than females. Patients over 80 years old accounted for 48. 15% . Two cases developed serious ADR due to drug interactions. ADR occurred during course of medication and after medication. ADR involved multiple systems and organs. CONCLUSION Voriconazote has multiple ADRs and can easily develop drug interactions. By focusing on monitoring, medical staff help to improve understanding of causes and characteristics of voriconazole, and increase ADR exposure rate of voriconazole. Therefore, clinical pharmacists can provide pharmaceutical services for promoting clinical rational use.

关 键 词：伏立康唑 不良反应 重点监测 临床药师 

分 类 号：R978.5[医药卫生—药品]